News from novartis pharmaceuticals canada inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Oct 08, 2014, 08:00 ET

(Pr)Lucentis® (ranibizumab) approved by Health Canada to treat vision loss resulting from choroidal neovascularization in pathologic myopia (mCNV)(1)

- Fourth indication for injection treatment that can stabilize and improve vision1 - mCNV a leading cause of visual impairment among...

Oct 01, 2014, 08:00 ET

Novartis announces Skin Impressions campaign launch on the first International Urticaria Day, to provide support to people living with severe skin diseases such as chronic idiopathic urticaria (CIU)

- Today is the first ever International Urticaria Day, an international event to increase urticaria awareness and improve care around the globe...

Aug 30, 2014, 11:12 ET

Novartis' investigational heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in PARADIGM-HF trial

- LCZ696 mortality benefit exceeded what was achieved with enalapril, an ACE-inhibitor, when replacing  enalapril combined with...

Jan 13, 2014, 14:36 ET

Novartis Pharmaceuticals Canada Inc. receives Health Canada approval for Ultibro™ Breezhaler®, a once-daily dual bronchodilator for COPD

- Ultibro™ Breezhaler®1 (QVA149), a long-term once-daily dual bronchodilator, received Health Canada approval on December 23rd 2013...

Dec 09, 2013, 07:00 ET

/R E P E A T -- Health Canada Approves Bexsero*, the First Vaccine Available to Prevent Meningococcal Serogroup B (MenB)(1,2)/

- Bexsero* is indicated to help protect individuals from two months through 17 years of age against meningococcal B disease, including...

Dec 09, 2013, 01:15 ET

Health Canada Approves Bexsero*, the First Vaccine Available to Prevent Meningococcal Serogroup B (MenB)(1,2)

- Bexsero* is indicated to help protect individuals from two months through 17 years of age against meningococcal B disease, including...

Nov 05, 2013, 07:00 ET

New Study Confirms Seasonal Flu Vaccine Designed for Seniors Improved Protection Against Influenzaˡ

DORVAL, QC, Nov. 5, 2013 /CNW/ - Newly published data in the medical journal Vaccine shows that FLUAD*, an influenza vaccine indicated...

Sep 09, 2013, 09:00 ET

Novartis continues to build its COPD pipeline and presents new data on investigational once-daily QVA149 at ERS

DORVAL, QC, Sept. 9, 2013 /CNW/ - Novartis announced new analyses of data for investigational QVA149 (indacaterol 85 mcg/glycopyrronium 43 mcg...

Sep 03, 2013, 08:00 ET

Now available in Ontario, (Pr)SEEBRI* BREEZHALER*, a long-term once-daily maintenance treatment for chronic obstructive pulmonary disease (COPD)

DORVAL, QC, Sept. 3, 2013 /CNW/ - Ontario patients suffering from chronic obstructive pulmonary disease (COPD) now have access to SEEBRI*...

Jan 16, 2013, 08:25 ET

Health Canada Approves (Pr)AFINITOR* in Advanced Breast Cancer for Women Battling This Disease

- Approval represents a development for Canadian patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer since...

Oct 31, 2012, 21:15 ET

Novartis Canada Resumes Seasonal Influenza Vaccine Distribution as Health Canada Lifts Suspension

Canadians urged to protect themselves for the coming flu season. Video: B-Roll - October 31, 2012: John Dorsey Head, Vaccines and Diagnostics...

Mar 28, 2012, 12:37 ET

Canadian Agency for Drugs and Technologies in Health (CADTH) recommends provincial and publicly funded drug plans reimburse (Pr)Lucentis* to treat vision loss resulting from diabetic macular edema (DME)

Positive recommendation based on treatment's efficacy and cost effectiveness DORVAL, Quebec, March 28, 2012 /PRNewswire/ - The Canadian Agency...